Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,605.00

Eli Lilly and Company (NYSE:LLY) had its price target increased by Scotiabank from $1,300.00 to $1,605.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a sector outperform rating on the stock.

A number of other research analysts also recently commented on LLY. HSBC increased their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a research report on Tuesday, September 15th. Finally, Wells Fargo & Company upped their price objective on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,398.43.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,415.64 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $834.19 and a 1 year high of $1,449.68. The business has a 50 day moving average of $1,197.72 and a 200-day moving average of $1,092.57. The company has a market capitalization of $1.33 trillion, a P/E ratio of 45.95, a P/E/G ratio of 1.80 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. Eli Lilly and Company’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $7.02 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.

Insiders Place Their Bets

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last 90 days. Corporate insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Pathway Financial Advisers LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 2,972 shares of the company’s stock valued at $3,439,000 after acquiring an additional 80 shares during the period. Kestra Private Wealth Services LLC lifted its position in shares of Eli Lilly and Company by 1.3% during the third quarter. Kestra Private Wealth Services LLC now owns 57,167 shares of the company’s stock worth $66,147,000 after purchasing an additional 752 shares in the last quarter. Jacksonville Wealth Management LLC lifted its position in Eli Lilly and Company by 2.6% in the third quarter. Jacksonville Wealth Management LLC now owns 518 shares of the company’s stock valued at $599,000 after acquiring an additional 13 shares during the last quarter. Guardian Wealth Management Inc. grew its holdings in Eli Lilly and Company by 2.9% during the third quarter. Guardian Wealth Management Inc. now owns 8,049 shares of the company’s stock worth $9,314,000 after acquiring an additional 226 shares during the period. Finally, Boston Trust Walden Corp lifted its stake in shares of Eli Lilly and Company by 1.0% during the 3rd quarter. Boston Trust Walden Corp now owns 3,328 shares of the company’s stock worth $3,851,000 after purchasing an additional 33 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.